What’s new at SeqOne?
New platform features, customer success stories, awards and other great news about SeqOne…. you’ll find it all here. Journalists, we have a dedicated page for you.
-
News Press release18 May 2022
We are hiring a VP of Platform Sales
VP of Platform Sales: SeqOne is a well-funded company developing state-of-the-art genomic analysis tools for clinical applications in the fields of cancer and rare disease. The company's vision is [...]
-
Events News Press release
18 May 2022
SeqOne Genomics and Global Diagnostic Solutions Limited (GDS) extend their collaboration in MENA
The companies will participate at the Precision Med Expo Dubai 24th and 25th of May 2022 Montpellier, France – Dubai, May 18, 2022 - SeqOne Genomics, provider of [...]
-
Events News Publications6 May 2022
SeqOne posters at the ESHG: using ML and big data to improve variant interpretation
SeqOne will be at the ESHG show in Vienna in hall X4 booth 664. We will be presenting four posters high-lighting various projects by SeqOne's [...]
-
News Press release4 February 2022
SeqOne Genomics selected as genomic analysis solution for CELIA (Comprehensive Genomic profiling impact) project, in collaboration with Illumina
The project aims to compare the clinical utility of broad-spectrum genomic profiling in the treatment of late-stage cancer patients with more traditional approaches that analyze [...]
-
News Press release
24 January 2022
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The funding will drive international deployment of the company’s next generation genomic analysis platform to enable personalized medicine in cancers as well as rare and [...]
-
News Press release
19 November 2021
SeqOne expands its commercial presence in Middle Eastern markets
Genomics analysis becomes more accessible in MENA region: a new era for genetic diagnostics Montpellier – November 16th 2021. SeqOne Genomics, a leader in the [...]
-
News Platform features
27 September 2021
SeqOne unlocks the power of Illumina’s TruSightTM Oncology 500
With the addition of the TSO500 pan-cancer NGS assay for genomic profiling of tumour samples, SeqOne now provides oncologists with the most comprehensive genomic data [...]
-
Events News
7 September 2021
ESHG 2021 Conference – Satellite symposium replay
With @Eurofins Biomnis, SeqOne recently held a symposium on CNV detection in exome data, performance comparisons with traditional method and the clinical impact of fast [...]
-
Events News
30 June 2021
AMP 2021 – Learn more about SeqOne and its somatic platform
Learn more about SeqOne and its somatic platform that can analyze small or large pan-cancer DNA/RNA panels and TMB, MSI, HRD signature for the therapeutic [...]
-
News
4 May 2021
Marie Dehem, the new SeqOne EMEA Sales & Business Manager precision Medicine, Oncology
We are very pleased to announce the appointment of Marie Dehem to the role of EMEA sales & business manager Precision Medicine, Oncology. Marie is molecular biologist specialized in oncology. She spent several [...]
-
News
22 March 2021
Myriam Guiral, the new SeqOne CCO EMEA & Biopharma Head
We are very pleased to announce the appointment of Myriam Guiral to the role of CCO EMEA & Biopharma Head. Myriam has more than 20 years of [...]
-
News
18 January 2021
Using molecular clocks to tell cancer time
We all know tracking metastatic cancer progression is vital for ongoing monitoring of cancer patients, but how do metastatic cancers arise in the first place? [...]
